Go Mediaction

Main Menu

  • Home
  • Medical field
  • Prescription drugs
  • Drug discovery
  • Medical diagnosis

Go Mediaction

Header Banner

Go Mediaction

  • Home
  • Medical field
  • Prescription drugs
  • Drug discovery
  • Medical diagnosis
Medical field
Home›Medical field›GLS expects further growth in the medical field with micro-needle technology

GLS expects further growth in the medical field with micro-needle technology

By Deborah A. Gray
March 27, 2022
0
0



March. 28. 2022




Korea time



Settings



Business
2022-03-28 08:59

GLS expects further growth in the medical field with micro-needle technology

Endoderma cosmetic product sold by GLS in Europe / Courtesy of Endoderma
Endoderma cosmetic product sold by GLS in Europe / Courtesy of Endoderma


By Kim Jae HeunGLS, a European business partner of Endoderma, is grateful to work with the Korean bio-enterprise company, which it believes holds great potential for medical use.

“The patented technology is truly impressive and leads to top-notch, science-backed products. We are proud to be on this journey as partners and to represent this technology especially for the European market,” said the GLS CEO Benedikt Burkhardt during an interview with The Korea Times on March 16.

Endoderma’s micro-needle technology, which delivers medication by attaching a patch with fine needles to the body, has enormous potential for different types of uses. This is especially true for cosmetic purposes, but the potential medical use of such innovative technology is also looming on the horizon.

“The technology bridges the gap between injections and dermal application, for example creams. I think that explains the huge potential of micro-needle technology,” Burkhardt said.

Burkhardt sees huge potential for this relatively young technology, which has already gained industry acceptance.

“As always, new application forms need to create trust and that takes time. However, Endoderma’s technology is already very well accepted and we see great potential for growth in the medical field. With the right partners in the good segments, this application form can be extremely efficient and useful for many people,” Burkhardt said. “GLS is grateful to share mutual values ​​with Endoderma such as trust, transparency and hard work to deliver excellent products with maximum effect to customers.”

Endoderma cosmetic product sold by GLS in Europe / Courtesy of Endoderma
Endoderma cosmetic product sold by GLS in Europe / Courtesy of Endoderma


By Kim Jae HeunGLS, a European business partner of Endoderma, is grateful to work with the Korean bio-enterprise company, which it believes holds great potential for medical use.

“The patented technology is truly impressive and leads to top-notch, science-backed products. We are proud to be on this journey as partners and to represent this technology especially for the European market,” said the GLS CEO Benedikt Burkhardt during an interview with The Korea Times on March 16.

Endoderma’s micro-needle technology, which delivers medication by attaching a patch with fine needles to the body, has enormous potential for different types of uses. This is especially true for cosmetic purposes, but the potential medical use of such innovative technology is also looming on the horizon.

“The technology bridges the gap between injections and dermal application, for example creams. I think that explains the huge potential of micro-needle technology,” Burkhardt said.

Burkhardt sees huge potential for this relatively young technology, which has already gained industry acceptance.

“As always, new application forms need to create trust and that takes time. However, Endoderma’s technology is already very well accepted and we see great potential for growth in the medical field. With the right partners in the good segments, this application form can be extremely efficient and useful for many people,” Burkhardt said. “GLS is grateful to share mutual values ​​with Endoderma such as trust, transparency and hard work to deliver excellent products with maximum effect to customers.”
























Korea time

Subscribe to the eNewsletter









































Categories

  • Drug discovery
  • Medical diagnosis
  • Medical field
  • Prescription drugs

Recent Posts

  • Drug Discovery Informatics Market growth opportunities to be exploited
  • key vendors, trends, analysis, segmentation, forecast to 2029 – Designer Women
  • Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report 2022 – ResearchAndMarkets.com
  • PROBE AND ACT ON PRESCRIPTION DRUGS ABUSE
  • Prescription Drug Consumption Market Size, Share and Forecast to 2028 | Pfizer, Roche, Sanofi, Johnson & Johnson, Merck & Co. (MSD) – Designer Women

Archives

  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • November 2020
  • September 2020
  • May 2020
  • March 2020
  • September 2019
  • May 2019
  • August 2018
  • December 2013
  • Privacy Policy
  • Terms and Conditions